Aclarion ACON 深 沪
等待开盘 11-06 09:30:00 美东时间
1.56
-0.180
-10.34%
华盛通- 最 高1.73
- 今 开1.73
- 成交量 1.13万股
- 最 低 1.555
- 昨 收 1.74
- 总市值 449.65万
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 1.555
- 委 比 0.00%
- 总股本 288.24万
- 历史最高 586116.00
- 量 比 0.77
- 振 幅 10.06%
- 历史最低 1.555
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Publishes CEO Letter; Notes Q3 Scan Volumes Up 85% YoY And Up 117% YtD
Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the Company’s momentum and value-creating priorities for the quarter ended September 30, 2026. "The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can off...
10-20 19:05
Aclarion to Present at the 20th Annual LD Micro Main Event
Aclarion (NASDAQ: ACON) will participate in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles. Brent Ness, CEO, will present on October 20, 2026, at 11:30 AM PT. The event features over 100 companies presenting to investors. Aclarion, a healthcare tech company, focuses on chronic low back pain with its Nociscan platform, which uses MRS and AI to help physicians identify painf...
10-13 11:00
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
Aclarion, Inc. has updated the enrollment criteria for its pivotal CLARITY clinical trial to accelerate patient recruitment. New criteria, now approved at nine of eleven active sites, aim to expand the eligible patient pool while maintaining scientific rigor. The Company anticipates a significant increase in enrollment pace and will update the initial readout timing by year-end based on Q4 progress. The overall trial duration remains on track, wi...
10-08 11:00
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health has joined Aclarion's CLARITY trial to evaluate Nociscan, a technology using MR Spectroscopy and AI to identify sources of chronic low back pain. The trial aims to demonstrate Nociscan's ability to improve surgical outcomes. NYU Langone, a leading spine care center, will contribute to the multi-center study, which includes 300 patients undergoing spine surgery. Nociscan has shown a 97% surgical success rate when all pain-causin...
09-29 11:00
Aclarion Announces University Of Arizona College Of Medicine - Phoenix As New Clinical Site In Its CLARITY Trial
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation Ten sites now actively enrolling in CLARITY study, a prospective, randomized cli...
08-20 19:01
Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc Evaluation
Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and...
08-12 19:04
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion, Inc. announced the issuance of a U.S. patent titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," enhancing their Nociscan workflow. The patent addresses challenges in MR Spectroscopy data capture, improving scan efficiency, consistency, and reproducibility across imaging centers. It complements Aclarion's existing portfolio of over 65 issued and pending patents globally, supporting their mission to help physicians identify chr...
08-12 11:00
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion, Inc. reported strong momentum in the first half of 2026, with a 141% year-over-year scan volume growth and 71% sequential growth, driven by increased physician engagement and commercial execution. The company expanded Nociscan utilization in the U.S. and U.K., secured reimbursement in the U.K., and partnered with PRIA Healthcare to establish payer coverage in the U.S. Progress continued toward the CLARITY trial readout, and intellectual...
07-29 11:00
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
Aclarion, Inc. presented two abstracts at the ASPN Annual Meeting highlighting Nociscan's clinical utility in chronic low back pain management. The first abstract demonstrated the successful integration of MRS technology into clinical workflows for identifying symptomatic discs, while the second presented a case study where Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes, achieving 95% pain relief. Nociscan...
07-21 11:00
Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chr...
07-07 19:06
